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Abstract
Background: The Notch pathway combined with other signalling molecules acts specifically for the development
of each blood cell type and differentiation stage. A causative role of Notch dysfunction in leukaemia development
has been found in many studies so, initially only for T- acute lymphoblastic leukaemia (T-ALL) but more recently
also for B cell and myeloid leukaemia. The aim of our study is to introduce a method for multiple direct analysis
of the Notch pathway partners in a population of only 500 or fewer cells. The notion of this method consists in
gaining insight into gene expression at the level of the malignant clone population. A small number of cells is a
significant limitation when working on primary cells either when freshly isolated or when analysed after several
days in cocultures.
Methods: The primers were designed to avoid genomic amplification through the selection of 3′ and 5′ primers
that hybridise with different exons. Cell lines and primary cells were collected and multiplex quantitative real-time
reverse transcription polymerase chain reaction (qRT-PCR) performed on a descending number of cells, ranging
from 2,500 cells up to 50 cells per sample, for the Notch pathway genes and other transcription factors important
for cell differentiation. ImageJ program, STATISTICA 13.1 software package and Student’s t-test were used for
statistical evaluation. We checked protein expression by western blot.
Results: We characterised the gene expression levels of Notch, Ikaros and Parp genes in leukaemia cell lines of
B and T origin and in primary leukaemia samples of limited size. We further compared our results to the cDNA
analysis obtained by total RNA isolation from a large number of cells as routinely performed in clinical laboratories,
and finally tested the method described on primary cells from leukaemia patients.
Conclusions: This rapid multiple gene expression analysis of a small population of cells provides efficient cell
classification determining malignant changes as an important additional information for clinical leukaemia
diagnostics as well as for in vitro studies of primary cells.
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Background
The Notch family of genes is involved in the develop-
mental routes and signalling pathways of many tissues
across species and has very little diversity from insects
to mammals [1]. However, its role is unique to the cell
type, even if the cells are closely related, such as blood
cells developing from the same hematopoietic stem cell.
The variability of the Notch targets across different cells
or cell differentiation step is also due to the ability to
cooperate with other signalling pathways and to activate
promoter sequences dependent on the chromatin status
and actual cellular program. Recent investigations asso-
ciate Notch signalling with super-enhancers, which serve
as regulatory switches and lead to whole chromatin
remodelling [2, 3]. Notch molecules and their ligands
are cell transmembrane proteins. The signalling cascade
begins with ligands binding to the Notch receptor in the
cell membrane. In mammals there are three Delta-like
ligands (Dll1, Dll3 and Dll4) and two Jagged ligands
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(JAG1 and JAG2), which can activate Notch receptors
(NOTCH1, NOTCH2, NOTCH3 and NOTCH4). Notch
receptors are first modulated through two cleavages by
specific proteases, and then the ligand binding causes a
third proteolytic cleavage via γ-secretase, the subsequent
release of the Notch intracellular domain (NICD) and its
nuclear relocation. In the nucleus this molecule forms a
large complex interacting with cofactors, such as the tran-
scription factor complex CSL (CBF1/Su (H)/Lag1), which
binds to a specific sequence, displaces a repressor complex
and activates transcription. In addition, a number of inter-
acting molecules, from modulators of ligand binding to
Notch inhibitors and competing factors, influence the out-
come of this signalling [1, 4]. Feedback loops regulate the
signalling length and may also have a role in establishing
the specificity of the response.
In haematopoiesis, Notch signalling is one of the
major regulators not only of lymphocyte but also mye-
loid development. It regulates several controlling steps
in hematopoietic cell differentiation and is responsible
for T cell commitment from the multipotent precursor
while blocking early B cell lymphopoesis. It is involved
in several checkpoints in thymic T cell development
and peripheral T cell differentiation [5–7], in the speci-
fication of B cell subsets in the spleen and also for den-
dritic cell function [8].
Notch was first proposed to have a causative role in
leukaemia development in 1996 [9]. Notch mutations or
chromosome translocations leading to hyper activation
are evident in nearly 60% of T cell acute lymphoblastic
leukaemia (T-ALL) patients [10, 11]. While Notch acti-
vation in B cell chronic lymphocytic leukaemia could
lead to apoptosis and growth arrest, in B cell chronic
lymphocytic leukaemia and several types of lymphomas,
its mutation and subsequent pathway activation can lead
to more aggressive forms of the disease [12–14]. In mul-
tiple myeloma, the appearance of plasma cell malignancy
and Notch activation strongly depend on the receptor
interaction with its ligands in the microenvironment [11].
The accumulation of data on the importance of Notch in
the process of leukemogenesis also led to the first clinical
trials where Notch inhibitors were used in the treatment
of T-ALL [15].
In this article, we characterised leukaemia cell lines of B
and T origin as well as primary leukaemia cells, according
to the expression of upstream and downstream elements
of the Notch signalling pathway. This type of data could,
depending on the cell type, contribute to the development
of more precise prognostic markers and tailored therapies.
We analysed gene expression by qRT-PCR using either
cDNA obtained from purified RNA which usually requires
at least one million cells or by performing reverse tran-
scription directly without previous RNA purification. We
titrated down the necessary cells for the former to a very
small number (five to 500). Therefore this method of rapid
gene expression analysis is applicable for an efficient
classification of cells and the determination of malignant
changes that could serve as potential diagnostic markers
in samples as small as 10 μl of peripheral blood.
Methods
Primer design
All data on eligible gene sequences were obtained from
the Ensembl Project database. All primers were designed
using publicly available software, such as Primer3Plus
and IDT Primer Quest Tool. For each gene of interest
three primers were constructed, two forward (F1 and
F2) and one reverse (R). The primers were designed to
avoid genomic amplification through the selection of 3′
and 5′ primers that hybridise with different exons. To
ensure that the primers had the same amplification effi-
ciency, we attempted to design them to have a similar
number of base pairs and similar melting temperatures
(Tm), a GC content around 50% and a maximum ΔG
value of the five bases from the 3′ end. The length of
the expected amplicon of the first polymerase chain re-
action (PCR) did not exceed 330 base pairs (bp), while
the length of the amplicon of the second PCR did not
exceed 200 bp. The uniqueness of binding to the human
genome was checked in BLAST. All primers were veri-
fied to not create homodimers, and it was ensured that
those used in the first PCR did not create heterodimers.
Primer compatibility and the size of the amplified frag-
ments were checked using the freely available software
program AmplifyX. PCR with primer pairs in the first
and second PCR were compared to determine the equal
primer efficacy.
Patients, cell lines and cell cultures
Cell lines were obtained from the German Collection of
Microorganisms and Cell Cultures, including Jurkat
(human T cell leukaemia cells), CLL (B chronic lympho-
cytic leukaemia cells); and 697 and Nalm 6 (both human
B cell precursor leukaemia cells). Cells were cultured in
RPMI-1640 medium supplemented with 10% foetal calf
serum (FCS, Sigma–Aldrich). Primary cells were col-
lected from peripheral blood of two newly diagnosed
patients. Patients were diagnosed with chronic lympho-
blastic leukaemia according to the World Health
Organisation (WHO) classification of haematolymphoid
malignancies using combined diagnostic information
from cytomorphology, cytochemistry, immunophenotyp-
ing, immunogenetics and molecular cytogenetics charac-
teristics. Informed consent and Ethics Review Board
approval by the Ethics Committee of the University of
Zagreb Medical School was obtained, and the experiments
were performed according to the Declaration of Helsinki.
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RNA isolation and preparation of cDNA
Total RNA was extracted using TRI Reagent (Sigma–
Aldrich) according to the manufacturer’s instructions.
The integrity and purity of isolated RNA was checked on
agarose gel by electrophoresis, measured on NanoVue (GE
Life Sciences) and 2 μg of RNA were retro-transcribed
using random hexamers (Roche) and PrimeScript (TaKaRa).
Direct reverse transcription from cell lysates and PCR
amplification
Cells were harvested when optimal density was reached,
rinsed twice with phosphate buffer saline, counted and
finally aliquoted. The multiplex PCR method was per-
formed as described by Peixioto [16], but with modifica-
tions we introduced in order to use 50 to 2,500 cells,
instead of single cells as originally described. The cells
were first snap frozen at − 80 °C, then heated to 65 °C
for two minutes, followed by 50 min at 42 °C, with
MuLV Reverse Transcriptase and 100 nM of 3′ gene
specific primers from Applied Biosystems. The product
obtained was used as a template in the first PCR amplifi-
cation, with 15 nM of F1 and R primer pair and with
Taq polymerase (Sigma–Aldrich). In the first and second
semi nested PCR with F2 and R primer pair, cDNA was
amplified for 15 and 35 cycles respectively. We designed
the primers for expression analysis by semi-nested PCR
for the amplification of NOTCH1, NOTCH2, NOTCH3,
Dll1, JAG1, Hes-1, Hey-1, NUMB, Aiolos (IKZF3),
PARP-1, PARG, RUNX, PAX-5 and PU.1 and for HPRT
(hypoxanthine phosphoribosyl transferase) as a house-
keeping gene. In addition to that, a literature search
confirmed that primers for NOTCH2 and JAG1 were
previously successfully applied [17, 18].
qRT-PCR
qRT-PCR was performed using a 7500 Fast Real-Time
PCR System in a 96-well plate. Each well contained 1X
SYBR Green PCR MASTER MIX (all reagents and in-
struments from Applied Biosystems), 150 nM of primers
and 1 μl of template, either from the first PCR amplifica-
tion where cDNA was obtained from total cells or from
cDNA obtained from purified RNA. PCR efficiency was
calculated from the slope of the amplification curve in
the exponential phase by means of linear regression soft-
ware and was higher than 90%. Melting curve analysis
was always used for determination of product specificity.
Western blotting
Total cell extracts were prepared using a lysis buffer
containing a cocktail of protease inhibitors, as previously
described [18]. Protein concentration was measured
according to Bradford and analysed using the western
blot chemiluminescence detection method. The primary
antibodies used were rabbit anti human-Notch2, rabbit
anti human-Hes1 (Cell Signalling Technology, USA),
rabbit anti human-PARP-1 and rabbit anti human-β-
actin (Santa Cruz).
Statistical analysis
The ImageJ program (provided by the National Institute
of Health, Bethesda, USA) was applied for densitometric
analysis. Statistical analysis was performed using the
STATISTICA 13.1 software package (Stat Soft Inc.,
USA). Student’s t-test was used for comparison of results
gained by the two different methods. The significance
level was set at p < 0.05.
Results
Transcription factor expression in human leukaemic cells
of B and T origin by RT-PCR
In the developmental decisions of B and T lymphogen-
esis, as well as in the development of certain types of
leukaemia, Notch signalling plays an important role.
Therefore, we analysed the different components of the
Notch pathway in four human leukaemia-derived cell
lines. We selected representative samples of a T cell leu-
kaemia (Jurkat), pre-B cell leukaemia (697 and Nalm 6),
and B chronic lymphocytic leukaemia (CLL) and ana-
lysed the expression of 14 genes via qRT-PCR. Most of
the genes we studied are involved in Notch signalling as
receptors (NOTCH-1, − 2, − 3), ligands (Dll1, JAG1) or
downstream effectors (HES-1, HEY-1) as well as inhibi-
tors (NUMB). Further, we analysed Aiolos (IKZF3),
PARP-1, PARG, RUNX, PAX-5 and PU.1, all of which
are involved in lymphocyte differentiation and develop-
ment (see Fig. 1).
Relative expression of Notch and PARP pathways are
presented on Fig. 2. We found that pre-B cells, 697 and
Nalm-6, expressed NOTCH2 but very low levels of
NOTCH1 and NOTCH3. Genes dependent on Notch
signalling pathway activation, such as HES1 and HEY,
were not expressed, and transcripts of only one ligand
type, JAG1, were present. On the other hand, genes that
determine B cell development, PAX-5 and PU.1, were
active. The expression of Aiolos, RUNX, PARP-1, PARG
and NUMB was high in comparison with that of the
reference gene. The cell line, representing B chronic
lymphocytic leukaemia cells (CLL) (see Fig. 2), showed a
high expression of NOTCH1 and NOTCH 2 but not
NOTCH3. These cells also expressed the downstream
effectors of Notch signalling, HES1 and HEY1. JAG1
ligand expression was also detected. Originating from B
cells, these cells also had PAX-5 and PU.1 transcription
factor expression (Fig. 2). The T cell leukaemia cells
(Jurkat) expressed NOTCH1, NOTCH 2, and NOTCH 3
and JAG1 receptors as well as downstream effectors of
active Notch signalling, HES1 and HEY1, with only a
modest expression of the Dll1 ligand. The expression of
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Fig. 1 Validation of primer design strategy. a Efficiency: PCR reactions amplifying cDNA fragments with F1 and F2 semi-nested primers should
have the same efficiency. The efficiency of the designed primers was tested on the mixture of all cell line cDNA samples. b Competition: 12
primers present in the same reaction should not interfere with each other. After the first multiplex PCR reaction using the cDNA mixture as a
template, separate PCR reactions were set on with semi-nested F2 primers to analyse the specificity of the reaction. M (100 bp DNA Ladder), all
amplicons cited with the name of the gene; longer amplicons produced by F1/R and shorter by F2/R primers
Fig. 2 Relative expression of Notch (upper panel) and PARP (lower panel) pathways by RT-PCR in cell lines of B and T cell origin (cDNA obtained
from Jurkat, 697, Nalm-6 and CLL cell lines). Relative expression by band densitometry after gel electrophoresis of PCR amplicons, normalised with
the level of HPRT expression. M ± SD of two independent experiments
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Aiolos was lower than what was found in B cells. RUNX
was highly expressed in all leukaemia samples. B cell
gene characteristics were not expressed, such as the B
lymphocyte-developmental master transcription factor
PAX-5 and PU.1. Transcription of the genes involved in
PARP-1 regulation, PARP-1 and PARG, was also de-
tected. For further analysis we have chosen NOTCH2,
PARP-1, HES-1, PAX-5 and Aiolos because of their dif-
ferential expression in the leukemic cells tested in Fig.2.
and their possible applicability as a fast diagnostic tool.
Relative quantification of transcription factors via
multiplex qRT-PCR
In order to achieve transcription factor expression at the
cell population level, challenging the more sophisticated
and expensive single cell multiplex qRT-PCR and seek-
ing to reduce the number of cells necessary when sam-
ples are derived from patients, we established a new fast,
simple and reliable method for gene expression analysis.
We conceived a modification of the single cell multiplex
RT-PCR method of Peixoto et al. [16]. In the first step
we constructed the primers according to a number of
conditions, as previously described. For each gene of
interest three primers were constructed, two forward (F1
and F2) and one reverse (R), to obtain better specificity
in a semi-nested PCR reaction. From our RT-PCR re-
sults, we chose differentially expressed genes across cell
lines of B and T lymphocyte origin and also genes that
could tell us more about the cell differentiation status.
Used together in the first multiplex PCR reaction, F1
and R primers from various genes did not mutually
interact (as shown in a competition test in Fig. 1b).
Further, to obtain reliable quantitative relations, the effi-
ciency of the F1 and F2 primers was shown to be equal
(Fig. 1). We prepared lysates from leukemic cells ranging
from 50 to 2,500 cells and performed direct reverse tran-
scription initiated by a set of gene-specific primers (R).
The obtained cDNA was first amplified in a multiplex
PCR reaction and then in separate, semi-nested reactions.
The results obtained from samples ranging from 50 to
2,500 cells revealed no significant inhibition of the PCR
reaction originating from higher cell number extracts
(Fig. 3a). Since the samples with 50 cells had slightly more
variability we selected the samples with 500 cells for fur-
ther analysis. The 500-cell samples proved to be just right
to avoid differences among single cell expression levels
while simplifying the manipulation steps, and yet the
number is small enough not to inhibit the PCR reaction
and to be obtainable from less than 10 μl blood for several
analyses.
Figure 3b represents the comparison of gene expres-
sion levels obtained by cDNA amplification. In the first
set of samples, the template was cDNA produced by re-
verse transcription of isolated total RNA (cDNA). In the
second set, the template was derived by direct reverse
transcription of RNA in cell lysates and subsequent 15 cy-
cles amplification of multiplex PCR reaction (PCRI). The
gene expression level is presented as a Delta Ct (Cycle
threshold) using the HPRT expression as a reference
value. Although there were slight differences in the levels
of expression between different templates, the relationship
between the levels of expression of various genes was un-
changed throughout all the experiments. The analysed
cells were 697, pre-B lymphocyte strain cells, which
showed a low expression of HES-1, a downstream effector
of Notch signalling, as expected in pre-B cells. Notch-2
Fig. 3 a) Quantitative analysis of gene expression in samples
obtained from cell lysates of different numbers of 697 cells. PCRI:
cDNA obtained by direct reverse transcription from lysates of 2,500;
1,500; 500 and 50 cells. b) Quantitative analysis of gene expression
in samples obtained from reverse transcription of total RNA isolate
(■ cDNA) and from cell lysates (□ PCRI) of 697 cells. Relative expression
was presented as ΔCt value normalised with HPRT gene expression.
ΔCt value of 10 means that there was no amplification. The results
presented were obtained from three different experiments and shown
as mean ± SD. Differences between the means was not statistically
significant (p > 0.05). cDNA: cDNA obtained from RNA isolated from
2 × 106 cells; PCR I: cDNA obtained by direct reverse transcription of
lysate from 500 cells
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and Aiolos were expressed moderately, while PARP-1 and
Pax-5 showed significant expression. Gene expression was
also compared using the PARP-1 expression level in order
to show that direct analysis preserved the same expression
ratio as classical reverse transcription cDNA.
Next, we applied this method to characterise the signal-
ling pathways in three additional lymphocyte cell lines. As
the primary purpose for developing this method was to
analyse a small number of cells in samples obtained from
patients, we also demonstrated the applicability of the
method on patient samples. Fig. 4 presents the analysis of
Notch- and PARP-1-related pathways in different cells of
B and T origin. Similar to 697 pre-B cells, Nalm6 showed
a very low expression of Hes1, which indicates the ab-
sence of Notch activity. The cells also expressed low
levels of Notch2 receptor. PARP-1 and Aiolos were
highly expressed, as was Pax-5, a B cell transcription
marker. Jurkat cells, on the contrary, demonstrated an in-
crease in Hes expression, a feature indicating an active
Notch pathway, which is characteristic of T lymphocyte
development. These cells expressed a higher level of the
Notch2 receptor when compared to 697 cells, but the B
cell marker Pax-5, as expected, was not present at all.
Cells obtained from the CLL line expressed Hes1, showing
a higher activity of the Notch pathway. Notch2 receptor
and Pax-5 were moderately expressed. The analysis of pri-
mary leukaemia cells showed that this method is also ap-
plicable to lymphocytes previously separated from blood
samples.
We also analysed the expression of Notch downstream
effectors and PARP signalling proteins (Fig. 5). Western
blot analysis of the cell lines tested confirmed the data
obtained by qRT-PCR. In Jurkat cells, Notch2 receptor
(FL) was expressed as well as its downstream target
Hes1, indicating the activity of the Notch pathway.
PARP-1 showed moderate expression. In the 697 cells,
Notch2 N terminal form (NTM) was highly expressed,
but no Hes-1 protein was detected. PARP-1 showed
higher expression levels in 697 cells in comparison with
other lines, similar to the results obtained by qRT-PCR.
Nalm6 cells also showed Notch-2 expression, but no
downstream activity leading to Hes1 expression was de-
tected. In CLL cells, Notch2 receptor was expressed, but
so was Hes1, indicating downstream Notch signalling
Fig. 4 Quantitative gene expression analysis in four human-derived cell lines and primary cells obtained from two patients (Sample 1 and 2). Cell
lysates obtained from 500 cells were reversely transcribed with gene-specific primers and amplified for 15 cycles in multiple PCR reaction. For
qRT-PCR reaction, the primer pairs were semi-nested. Expression levels are presented as ΔCt values
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activity. PARP-1 showed a lower level of expression in
comparison to pre-B cells.
Discussion
Certain genes interfere with Notch signalling at promoter
(such as Aiolos) [19, 20] and PARP-1 levels [21, 22]. PARG
interferes with PARP-1 pathways and could be indirectly
involved in Notch signalling. Runx is a transcription factor
involved in blood cell development [23], as are Pax-5 and
Pu.1, which are characteristic master transcription factors
directing B cell development [23–25].
The genes analysed were those involved in Notch signal-
ling (Hes1, Notch2), Pax-5 as a B cell marker, PARP-1 and
Aiolos, an Ikaros family member involved in B cell differ-
entiation. Notch2 was chosen as the most expressed
Notch receptor in different cell lines and Hes-1 as an indi-
cator of Notch pathway activity. Therefore, in this article,
we analysed the expression of genes involved in lympho-
cyte differentiation in several B and T leukaemia cell lines
as well as in samples obtained from leukaemia patients.
The focus was on the Notch signalling pathway as one of
the main pathways determining the diversification be-
tween B and T cells.
The 697 and Nalm-6 pre-B cell lines showed typical
expression of B cell origin genes: the presence of Pax-5
and Pu.1 and the absence of an active Notch pathway, as
demonstrated by the repression of downstream targets
of cleaved NOTCH, HES and HEY genes. It was found
that cells do express Notch receptors, with Notch-2 as
the dominant form, as well as some ligands (such as
JAG1). Inactive Notch signalling was also confirmed at
the protein level. In general, B cells during development
show low Notch signalling activity, although Notch was
found to have a role in marginal zone B cells.
Another B cell line, CLL, showed, in addition to the
expression of Notch receptors and low levels of ligands,
the expression of all Notch downstream targets we
analysed, indicating signalling activity. Hes-1 protein
was also detected at the protein level. This result is in
accordance with the recently described subset of CLL,
where a mutation in the Notch-1 PEST domain increases
Notch half-life and contributes to the aggressiveness of
the disease [26, 27]. The detection of downstream Notch
targets indicates the role of this pathway in the aetiology
of CLL.
Jurkat cells have an active Notch pathway at the RNA
and protein levels. These data are in concordance with
the known role of Notch in T cell differentiation. Consti-
tutive Notch signalling is involved in T cell malignancies,
where it interferes with differentiation, proliferation and
survival [28]. In order to obtain insight into the gene ex-
pression of the malignant clone at the population level
we utilised the method described by Peixioto et al. [16]
for single cells but in a population of cells as small as
500 for multiple direct analysis of the Notch pathway
partners. A small number of cells is a significant limita-
tion when working on primary cells, especially when
dealing with very small samples of tissue or paediatric
samples. The method provided the same results as PCR
from isolated total RNA. This newly introduced method
is a short-cut technique for detecting key Notch and
Parp gene expression. Namely, the development of new
technologies enables scientists to analyse RNA expres-
sion at the level of one cell, and even to detect the exist-
ence of only two molecules of DNA. These methods are
valuable when only a small number, or only one cell, is
available, such as in the case of early embryonic cells.
Moreover, these methods make the analysis of differ-
ences among cells in a cell population possible. Such
analyses from several studies indicate the existence of
variability among gene expression profiles in cells of the
same type within a population. At the same time, these
techniques require laborious validation, as the resultant
values originate from the unique cell, and only the reli-
ability of the method proves the diversity among entities.
This variability in gene expression among single cells is
avoided when analysing several hundred cells at the
same time [17]. Our method has been proven to be sen-
sitive, and the results obtained are in concordance with
those of methods involving the RNA isolation step as
well as with protein analysis. Multiplex PCR reaction en-
ables amplification of rare sequences, avoiding their loss.
Small differences that appear in expression levels be-
tween samples obtained in different ways likely stem
from two-step PCR reactions applied in direct analysis.
Fig. 5 Western blot analysis of Notch signalling molecules in
leukaemia cell lines. Whole-cell extracts were subjected to
immunoblot analysis and incubated with antibodies binding to
Notch2, Hes1, PARP1 and β-actin as a loading control. Cell lines:
Jurkat, 697, Nalm-6 and CLL
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Differences also occur when different types of reverse
transcription reactions are applied, i.e. depending on the
primers used (random or specific primers or oligo dT)
(data not shown). It should be emphasised that primer
design is the most critical step. Although all primer pairs
were checked for their efficiency, it is still possible that
small differences existed. On the other hand, it is con-
ceivable that the presence of other components of cell
lysates influenced the results. Nonetheless, the ratio of
gene expression in the multiplex reaction was preserved
when compared with cDNA amplification. The advan-
tages of this method are, besides the small number of
cells necessary for the tests, the simple, straight-forward
sample preparation, direct approach and simultaneous
analysis of the desired set of genes. In addition, along
with cell sorting it enables the analysis of small popula-
tions of cells (e.g. stem cells) in small biological samples.
These features are especially important in conditions
when only small samples are available, such as in paedi-
atric samples, as well as when fast and simple diagnostic
methods are required. Also, our method is relevant for a
laboratory where only few cell culture cells are available
that cannot be processed through a cell sorter or for a
medical centre where a fast reliable result is required in
spite of a sophisticated cell sorter facility. Uncovering
the underlying processes that contribute to the leukemic
transformation or the maintenance of leukemic cells could
potentially lead to the development of more efficient and
precise therapeutic strategies.
Further the results presented here regarding Notch
signalling analysis in leukaemia samples could contribute
to efficient and person-oriented therapy in the future.
Conclusion
In this article, we characterise leukaemia cell lines of B
and T origin, as well as primary leukaemia cells, according
to the expression of upstream and downstream elements
of the Notch signalling pathway. For this work, we intro-
duced a newly designed method of rapid expression ana-
lysis applicable for the efficient classification of cells and
determination of malignant changes that could serve as
potential markers in leukaemia diagnostics.
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